Related Articles
HSCT for Severe Autoimmune Diseases
Despite the innovations of new biologics and disease-modifying anti-rheumatic drugs, a large unmet need remains for patients with rheumatic autoimmune disease. Treatment remains limited for many conditions, including for conditions with a dim prognosis, such as systemic sclerosis.1 One promising treatment avenue is hematopoietic stem-cell transplantation (HSCT). Here, we provide background on HSCT for severe…
The History of ACE Inhibitors in Scleroderma Renal Crisis
Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…
Cellular Therapy of Autoimmune Disease
Is a novel treatment breakthrough on the horizon?
In Memoriam: Samuel Strober, MD
Samuel Strober was born on May 8, 1940, in Brooklyn, N.Y., the oldest son of Lee and Julius Strober. Sam attended Public School 92 in Brooklyn and Stuyvesant High School in Manhattan, and graduated from Columbia College, New York, in 1961, and Harvard Medical School, Boston, in 1966. While in high school, Sam won a…